Skip to content

Implantable Cardiac Monitor to Detect Atrial Fibrillation in Patients With MINOCA

Implantable Cardiac Monitor to Detect Atrial Fibrillation in Patients With MINOCA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05326828
Acronym
MINOCA
Enrollment
60
Registered
2022-04-14
Start date
2022-05-24
Completion date
2031-05-15
Last updated
2024-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, MINOCA

Keywords

Implantable cardiac monitor

Brief summary

Myocardial infarction with non-obstructive coronary arteries (MINOCA) (i.e.\<50% stenoses) on coronary angiography) is an underappreciated clinical entity concerning 5-6% of patients with acute myocardial infarction. Approximately 50% of these patients remain without appropriate diagnosis and treatment. The MINOCA study aims at systematically assessing the frequency of underlying pathologies of MINOCA and outcomes with a multidisciplinary etiologic work-up and follow-up of 5 years including, for the first time, an implantable cardiac monitor (ICM) to assess the frequency of atrial fibrillation as underlying cause for MINOCA.

Detailed description

Approximately 5-6% of patients with acute myocardial infarction (AMI) have myocardial infarction with non-obstructive coronary arteries (MINOCA) (i.e.\<50% stenoses) on coronary angiography and up to 50% of these patients remain without appropriate diagnosis and treatment. A multidisciplinary etiologic work-up of MINOCA has recently been proposed by international consensus documents. The present study aims for a structured scientific data collection from a full guideline-based work-up after MINOCA and follow-up of 5 years to assess clinical outcomes. Untreated atrial fibrillation is a potentially neglected underlying cause of MINOCA. As implantable cardiac monitors (ICM) can detect atrial fibrillation with high accuracy, the aim of this study is, for the first time, to assess the occurrence of first diagnosed atrial fibrillation with the use of ICM in patients with MINOCA. To allow for an all-comers data collection, patients with contraindication(s) to ICM implantation will be enrolled into the non-ICM group to assess the frequency of underlying causes of MINOCA and clinical outcomes throughout 5 years.

Interventions

DEVICECONFIRM Rx implantable cardiac rhythm monitor (Abbott)

Implantation of CONFIRM Rx ICM

DIAGNOSTIC_TESTSystematic etiologic work-up for underlying causes of MINOCA

Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)

Sponsors

University Hospital, Zürich
CollaboratorOTHER
Bangerter-Rhyner Stiftung
CollaboratorUNKNOWN
Abbott
CollaboratorINDUSTRY
Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

ICM group 1. ≥18 years of age 2. Written informed consent 3. Acute myocardial infarction (AMI) type 1 in accordance with the 4th universal definition of myocardial infarction 4. Non-obstructive coronary arteries on angiography defined as the absence of coronary artery stenoses ≥50% in any potential infarct-related artery 5. No clinically overt specific cause for the acute presentation 6. Subendocardial or transmural late gadolinum enhancement (LGE) consistent with an ischemic etiology on cardiac magnetic resonance imaging (CMR) 7. No clear underlying cause of MINOCA and therefore increased probability of atrial fibrillation

Exclusion criteria

ICM group: 1. Known atrial fibrillation or atrial flutter 2. History of atrial fibrillation or atrial flutter ablation 3. Known coronary artery disease 4. Previous MI 5. Previous percutaneous coronary intervention (PCI) 6. Previous coronary artery bypass grafting (CABG) 7. Contraindications to CMR (i.e. non-MR-compatible implantable cardiac device, glomerular filtration rate (GFR) \<30 ml/min) 8. Contraindications to ICM implantation 9. Clear underlying cause of MINOCA before ICM implantation Inclusion Criteria non-ICM group: 1. ≥18 years of age 2. Written informed consent 3. AMI type 1 in accordance with the 4th universal definition of myocardial infarction 4. Non-obstructive coronary arteries on angiography defined as the absence of coronary artery stenoses ≥50% in any potential infarct-related artery 5. No clinically overt specific cause for the acute presentation 6. Subendocardial or transmural LGE consistent with an ischemic etiology on CMR

Design outcomes

Primary

MeasureTime frameDescription
ICM group: Atrial fibrillation1 yearThe occurrence of first diagnosed atrial fibrillation in patients with MINOCA according to ICM
Non-ICM group: Frequency of underlying causes of MINOCA1 yearThe frequency of underlying causes of MINOCA (i.e. plaque rupture, plaque erosion, coronary thrombus, coronary dissection, eruptive calcific nodule, coronary spasm (including microvascular dysfunction), coronary thromboembolism due to intra- or extracardiac sources of thrombi (including thromboembolism in the context of a persistent foramen ovale (PFO)), atrial fibrillation according to 3 7-day-Holter-ECGs, other sources of coronary embolism (e.g. vegetations, complex aortic plaques), and arterial thrombophilia

Secondary

MeasureTime frameDescription
ICM group: Atrial fibrillation burden~2 years (battery end of life or explantation of ICM)Time spent in atrial fibrillation divided by total rhythm monitoring time x100 (%)
ICM group: First diagnosis of atrial fibrillation, stroke or death1 yearTime to composite of first diagnosis of atrial fibrillation, stroke or death
ICM group: Other brady- or tachyarrhythmias~2 years (battery end of life or explantation of ICM)The incidence and time to first occurrence of other brady- or tachyarrhythmias
ICM group: Time to first diagnosed atrial fibrillation~2 years (battery end of life or explantation of ICM)Time to first occurrence of atrial fibrillation according to ICM
ICM group: Frequency of non atrial fibrillation related etiologies of MINOCA1 yearThe frequency of non atrial fibrillation related etiologies of MINOCA (i.e. plaque rupture, plaque erosion, coronary thrombus, coronary dissection, eruptive calcific nodule, coronary spasm (including microvascular dysfunction), coronary thromboembolism due to other intra- or extracardiac sources of thrombi not related to atrial fibrillation (including thromboembolism in the context PFO), other sources of coronary embolism (e.g. vegetations, complex aortic plaques), and arterial thrombophilia
Both groups: Clinical outcomes5 yearsThe occurrence of all-cause death, cardiac death, myocardial infarction, coronary revascularization, stroke, transitory ischemic attack, deep vein thrombosis, pulmonary embolism, and systemic arterial thromboembolism
ICM group: Predictive value of CMR parameters for atrial fibrillation~2 years (battery end of life or explantation of ICM)Predictive value of atrial parameters of CMR imaging for the diagnosis of atrial fibrillation
ICM group: Time to different durations of first diagnosed atrial fibrillation~2 years (battery end of life or explantation of ICM)Time to first diagnosis of atrial fibrillation (lasting ≥30 seconds; ≥6 minutes; ≥1 hour; ≥ 24 hour)

Countries

Switzerland

Contacts

Primary ContactLorenz Räber, MD, PhD
lorenz.raeber@insel.ch+41 31 632 50 00
Backup ContactSarah Bär, MD
sarah.baer@insel.ch

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026